Anti psychotics Market

Market Definition, Market Size, Forecasted Value, CAGR Value
Anti-psychotics market refers to the pharmaceuticals used to manage conditions like schizophrenia, bipolar disorder, and other mental health disorders. The global anti-psychotics market size was valued at USD 14.6 billion in 2020 and is projected to reach USD 20.3 billion by 2027, with a CAGR of 4.5% during the forecast period.

Market Overview
Market for anti-psychotics is primarily driven by the increasing prevalence of mental health disorders worldwide. Factors such as rising awareness, better diagnosis, and a growing elderly population contribute to market growth.

Market Dynamics

Drivers: Increased mental health awareness, advancements in drug delivery systems, and rising healthcare expenditure.
Restraints: Side effects associated with anti-psychotic medications, stringent regulatory requirements, and the high cost of novel drugs.
Challenges: Patent expiration of key drugs, leading to generic competition, and the stigma associated with mental health disorders.
Opportunities: Emerging markets, novel drug development, and personalized medicine approaches.
 

Key Insights in Different Regions

US: Largest market due to high prevalence of mental health disorders and favorable reimbursement policies.
Europe: Significant market share, driven by a growing elderly population and increasing awareness.
Japan: Growing market, supported by technological advancements and government initiatives.
China: Rapidly expanding market due to increasing healthcare expenditure and improving healthcare infrastructure.
India: Emerging market with high unmet needs and increasing government focus on mental health.
 

Regional Status
US dominates the global anti-psychotics market, followed by Europe and Asia Pacific. China and India are expected to witness the fastest growth due to improving healthcare infrastructure and rising awareness.

Market Segmentations
Market is segmented by drug class (first-generation, second-generation, and third-generation anti-psychotics), application (schizophrenia, bipolar disorder, and others), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies). The fastest-growing segment is expected to be second-generation anti-psychotics, driven by their efficacy and lower risk of side effects.

Major Companies Operating in Different Regions

Pfizer (US)
Johnson & Johnson (US)
Eli Lilly and Company (US)
AstraZeneca (UK)
Bristol-Myers Squibb (US)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
GlaxoSmithKline plc (UK)
 

Latest News & Recent Developments

Pfizer acquired Array BioPharma to expand its oncology portfolio.
Johnson & Johnson announced the acquisition of Momenta Pharmaceuticals to strengthen its autoimmune disease pipeline.
AstraZeneca launched a new anti-psychotic medication, Saphris, in the US market.
Otsuka Pharmaceutical Co., Ltd. received FDA approval for its digital medicine system, Abilify MyCite, for schizophrenia treatment.
 

Market Segmentation

By Drug Class:
First-Generation Anti-psychotics
Second-Generation Anti-psychotics
Third-Generation Anti-psychotics
By Application:
Schizophrenia
Bipolar Disorder
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
 

Report Highlights

Growing demand for second-generation anti-psychotics.
Increasing investment in research and development of novel drugs.
Rising adoption of personalized medicine approaches.
 

Most Frequently Asked Questions

What are the key factors driving the growth of the anti-psychotics market?
Which region is expected to witness the fastest growth in the anti-psychotics market?
What are the major challenges faced by companies operating in the anti-psychotics market?
How is the competitive landscape of the anti-psychotics market evolving?